

BRIEF REPORT

Rapid Eye Movement Sleep Behavior Disorder: Abnormal Cardiac Image and Progressive Abnormal Metabolic Brain Pattern

Annette Janzen, MD,^{1*} Rosalie V. Kogan, MD,² Sanne K. Meles, MD, PhD,³ Elisabeth Sittig,¹ Remco J. Renken, PhD,⁴ Fanni F. Geibl, MD, PhD,¹ Jan Booij, MD, PhD,⁵ Gilles Stormezand, MD,² Markus Luster, MD,⁶ Geert Mayer, MD,¹ Klaus L. Leenders, MD, PhD,^{2,3} and Wolfgang H. Oertel, MD, PhD^{1,7}

¹Department of Neurology, Philipps-University Marburg, Marburg, Germany ²Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands ³Department of Neurology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands ⁴Cognitive Neuroscience Center, Department of Biomedical Sciences of Cells & Systems, University of Groningen, Groningen, the Netherlands ⁵Department of Radiology and Nuclear Medicine, Amsterdam UMC, Academic Medical Center Amsterdam, Amsterdam, the Netherlands ⁶Department of Nuclear Medicine, Philipps-University Marburg, Marburg, Germany ⁷Institute for Neurogenomics, Helmholtz Center for Health and Environment, Munich, Germany

ABSTRACT: Background: Isolated rapid eye movement sleep behavior disorder (iRBD) is prodromal for α -synucleinopathies.

Objective: The aim of this study was to determine whether pathological cardiac [¹²³I]meta-iodobenzylguanidine scintigraphy ([¹²³I]MIBG) is associated with progression of [¹⁸F]fluorodeoxyglucose-

positron emission tomography-based Parkinson's disease (PD)-related brain pattern (PDRP) expression in iRBD.

Methods: Seventeen subjects with iRBD underwent [¹⁸F]fluorodeoxyglucose-positron emission tomography brain imaging twice ~3.6 years apart. In addition, [¹²³I]MIBG and [¹²³I]N- ω -fluoropropyl-2 β -carbomethoxy-3 β -(4-iodophenyl)nortropane single-photon emission computed tomography ([¹²³I]FP-CIT-SPECT) at baseline were performed. Olfactory, cognitive, and motor functions were tested annually.

Results: Twelve of 17 subjects had pathological [¹²³I]MIBG. At baseline, 6 of 12 of these expressed the PDRP (suprathreshold PDRP z score). At follow-up, 12 of 17 subjects had suprathreshold PDRP z scores, associated with pathological [¹²³I]MIBG in 92% and with pathological [¹²³I]FP-CIT-SPECT in 75%. Subjects with pathological [¹²³I]MIBG had higher PDRP z score change per year ($P = 0.027$). Three subjects phenoconverted to PD; all had pathological [¹²³I]MIBG and [¹²³I]FP-CIT-SPECT, suprathreshold baseline PDRP z scores, and hyposmia.

Conclusions: Pathological [¹²³I]MIBG was associated with progressive and suprathreshold PDRP z scores at follow-up. Abnormal [¹²³I]MIBG likely identifies iRBD as prodromal PD earlier than pathological [¹²³I]FP-CIT-SPECT. © 2021 The Authors. *Movement Disorders* published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society

Key Words: isolated rapid eye movement sleep behavior disorder; [¹²³I]MIBG scintigraphy; [¹⁸F]FDG-PET-derived Parkinson's disease-related pattern; hyposmia; prodromal progression biomarker

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

*Correspondence to: Dr. Annette Janzen, Department of Neurology, Philipps-University Marburg (UMR), Baldingerstrasse, D-35043 Marburg, Germany; E-mail: janzena@med.uni-marburg.de

Annette Janzen, Rosalie V. Kogan, Klaus L. Leenders, and Wolfgang H. Oertel contributed equally to this work.

Relevant conflicts of interest/financial disclosures: This study was supported by Dutch "Stichting ParkinsonFonds" and the German "ParkinsonFonds Deutschland".

Full financial disclosures and author roles may be found in the online version of this article.

Received: 2 July 2021; **Revised:** 29 October 2021; **Accepted:** 29 October 2021

Published online in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/mds.28859

Isolated rapid eye movement sleep behavior disorder (iRBD) is prodromal for α -synucleinopathies (Parkinson's disease [PD], dementia with Lewy bodies [DLB], multiple system atrophy [MSA]) in 80%–90% of cases.^{1,2}

Most patients with iRBD will convert to PD or DLB, and this will be important for future disease-modifying therapies at premotor stages. This necessitates biomarkers for the prediction and monitoring of disease progression. Equally important, such biomarkers should identify patients with iRBD who will *not* phenoconvert.

iRBD is associated with abnormalities in cognition,³ olfaction,^{4,5} motor function,³ autonomic functions,³ cardiac noradrenergic innervation as assessed by [¹²³I]meta-iodobenzylguanidine scintigraphy ([¹²³I]MIBG),^{6,7} striatal dopaminergic innervation as visualized by [¹²³I]N- ω -fluoropropyl-2 β -carbomethoxy-3 β -(4-iodophenyl)nortropane single-photon emission computed

tomography ($[^{123}\text{I}]\text{FP-CIT-SPECT}$),^{8,9} and cerebral glucose metabolism as visualized by $[^{18}\text{F}]\text{fluorodeoxyglucose-positron emission tomography}$ ($[^{18}\text{F}]\text{FDG-PET}$).^{10,11} By combining $[^{18}\text{F}]\text{FDG-PET}$ with the computational algorithm Scaled Subprofile Model/principal component analysis, a robust pattern of altered brain glucose metabolism has been identified in PD: the PD-related pattern (PDRP).^{12,13} This technique allows quantification of PDRP expression on a case-by-case basis, denoted by a z score.^{12–15} PDRP expression can be considered a PD progression marker and was also observed in independent iRBD cohorts (ie, in prodromal PD).^{10,16,17}

Recently, we reported that the degree of PDRP expression, and changes therein, may be suitable as a nondopaminergic progression biomarker in iRBD. In that study, 4 of 8 subjects with suprathreshold baseline PDRP z scores ($z > 1.98$; for details, see Kogan et al.¹⁸) converted to PD, and 6 of 12 subjects with lower baseline PDRP z scores progressed to suprathreshold PDRP z scores at 3.6-year-follow-up.¹⁸

Therefore, we investigated whether $[^{123}\text{I}]\text{MIBG}$ ^{6,7,19} could stratify patients with iRBD into those with a fast rate of PDRP z score progression and imminent phenoconversion to PD/DLB versus those with a slower progression rate. $[^{123}\text{I}]\text{MIBG}$ has been reported to be impaired early in the course of iRBD before nigrostriatal degeneration.^{20–22} In addition, pathological $[^{123}\text{I}]\text{MIBG}$ has been shown to correlate with olfactory dysfunction in PD.^{23,24} Because hyposmia is one of the earliest prodromal PD/DLB symptoms,^{4,5} we also studied the correlation of cardiac $[^{123}\text{I}]\text{MIBG}$ uptake with olfactory function. Complementarily, we used $[^{123}\text{I}]\text{FP-CIT-SPECT}$.⁸ Cognitive and motor functions were clinically assessed to detect phenoconversion.

Patients and Methods

Study Design

The study design, details of enrolled subjects, and criteria of phenoconversion to PD/DLB have been published previously.¹⁸ The study protocols were approved by both institutional review boards (University Medical Center Groningen, the Netherlands; University Marburg, Germany). According to the Declaration of Helsinki, all subjects gave their voluntary informed consent after verbal and written explanation of the study (Netherlands Trial Register: NL8057). This report focuses on the previously described 17 German subjects with iRBD.¹⁸

Imaging

All 17 subjects with iRBD underwent serial $[^{18}\text{F}]\text{FDG-PET}$ brain imaging and baseline $[^{123}\text{I}]\text{FP-CIT-SPECT}$, with scanning, reconstruction, and analysis

protocols as previously published.^{10,18} Fifteen $[^{123}\text{I}]\text{MIBGs}$ were performed at baseline, and another 2 after the second $[^{18}\text{F}]\text{FDG-PET}$. For details, see Supporting Information.

Clinical Tests

The Sniffin' Sticks 16-item odor identification test (pathological: scores $\leq 10/16$),²⁵ the Montreal Cognitive Assessment (MoCA; pathological: scores $\leq 25/30$),²⁶ and the Unified Parkinson's Disease Rating Scale-motor, Part III (UPDRS-III)²⁷ were performed annually.

Statistical Analysis

Variables were tested for normality of distribution with the Shapiro-Wilk test. Normally distributed variables are given in mean $\pm$ standard deviation, and nonparametric variables as median and interquartile range. Due to small subgroup size, nonparametric tests were used: the Mann-Whitney U test to examine changes between both subgroups (iRBD with reduced versus normal $[^{123}\text{I}]\text{MIBG}$) and a one-sample Wilcoxon signed-rank test for changes within subgroups. Values were considered to be significant at $P < 0.05$. All analyses were performed using SPSS v27 (SPSS, Chicago, IL). See also Supporting Information Methods.

Results

Clinical, demographic, and imaging data of all subjects are summarized in the Supporting Information Results and Table S1.

$[^{123}\text{I}]\text{MIBG}$

Twelve of 17 subjects had an abnormal $[^{123}\text{I}]\text{MIBG}$ (11 at baseline, 1 after the follow-up $[^{18}\text{F}]\text{FDG-PET}$), and 5 of 17 subjects had a normal $[^{123}\text{I}]\text{MIBG}$ (4 at baseline, 1 after follow-up $[^{18}\text{F}]\text{FDG-PET}$; see Supporting Information). For the demographic, clinical, and imaging data of the two subgroups and the statistical analysis, see Table 1.

$[^{18}\text{F}]\text{FDG-PET}$

At baseline, 6 of 12 (50%) subjects with abnormal $[^{123}\text{I}]\text{MIBG}$ expressed suprathreshold PDRP z scores. Of these, five subjects had abnormal baseline $[^{123}\text{I}]\text{FP-CIT-SPECT}$ (Fig. 1B,C; Supporting Information Table S1). At follow-up $[^{18}\text{F}]\text{FDG-PET}$, 11 of 12 (92%) subjects with abnormal $[^{123}\text{I}]\text{MIBG}$ had suprathreshold PDRP z scores, of whom 9 had pathological baseline $[^{123}\text{I}]\text{FP-CIT-SPECTs}$. Of the three subjects with pathological $[^{123}\text{I}]\text{MIBG}$ and normal baseline $[^{123}\text{I}]\text{FP-CIT-SPECT}$, one had subthreshold PDRP z scores at baseline and follow-up, one progressed from

TABLE 1 Demographic and clinical data: subgroup analysis

RBD subjects with normal [123 I]MIBG vs. RBD subjects with abnormal [123 I]MIBG ^a			
	RBD Subjects with Normal [123 I] MIBG (n = 5)	RBD Subjects with Abnormal [123 I] MIBG (n = 12)	P Value
Male sex, n (%)	4 (80)	11 (92)	
Age (y)			
Baseline	60.9 ± 6.4	63.5 ± 5.3	0.646
Follow-up	64.6 ± 6.3	67.1 ± 5.5	0.721
RBD duration at follow-up (y)	10.0 (7.6–19.2)	7.8 (6.2–9.6)	0.184
PDRP z score			
Baseline	−0.44 ± 1.31	1.85 ± 2.07	0.048
Follow-up	0.95 ± 1.09	4.3 ± 2.67	0.006
Change from baseline to follow-up	1.39 ± 0.95	2.45 ± 1.15	0.104
Change per year	0.35 ± 0.21	0.69 ± 0.31	0.027
[123 I]MIBG-HMR value	1.6 (1.56–1.73)	1.17 (1.10–1.22)	0.001
Lowest putaminal DAT binding value	2.38 ± 0.18	1.66 ± 0.51	0.010
Lowest caudatal DAT binding value	2.87 ± 0.28	2.19 ± 0.52	0.004
UPDRS-III score			
Baseline	4.0 (1.0–5.0)	2.0 (1.0–4.0)	0.600
Follow-up	2.0 (0.5–5.0)	3.5 (2.3–6.3)	0.282
Odor identification score			
Baseline	10.6 ± 3.2	6.3 ± 4.1	0.053
Follow-up	12.0 ± 2.4	5.3 ± 4.2	0.003
MoCA			
Baseline	27.0 (24.5–29.0)	27.0 (26.0–28.0)	0.884
Follow-up	28.0 (27.5–29.5)	28 (27.0–29.0)	0.528
Baseline vs. follow-up in RBD subjects with normal or abnormal [123 I]MIBG ^b			
	RBD Subjects with Normal [123 I]MIBG (n = 5), P Value	RBD Subjects with Abnormal [123 I]MIBG (n = 12), P Value	
PDRP z score: baseline vs. follow-up	0.063	<0.001	
UPDRS-III: baseline vs. follow-up	1.000	0.324	
Odor identification score: baseline vs. follow-up	0.250	0.063	
MoCA: baseline vs. follow-up	0.500	0.059	

Bold values denote significant P values.

^aNormally distributed values are shown as mean ± standard deviation and nonparametric values as median (interquartile range). Nonparametric Mann-Whitney U test was used to compare subgroups with normal versus abnormal [123 I]MIBG.

^bWilcoxon test was used to compare baseline and follow-up results within each group.

RBD, rapid eye movement sleep behavior disorder; [123 I]MIBG, [123 I]meta-iodobenzylguanidine scintigraphy; PDRP, Parkinson's disease-related brain pattern; HMR, heart-to-mediastinum ratio; DAT, dopamine transporter; UPDRS-III, Unified Parkinson's Disease Rating Scale-motor, Part III; MoCA, Montreal Cognitive Assessment.

subthreshold to suprathreshold z score at follow-up, and one had suprathreshold z scores at baseline and follow-up (Fig. 1B; Supporting Information Table S1).

All five subjects with normal [123 I]MIBG had subthreshold baseline PDRP z scores, with all but one still

having subthreshold PDRP z scores at follow-up. This one subject ($z = 2.07$ at follow-up) was the second oldest of the iRBD cohort (72.5 years old at follow-up).

The 12 subjects with abnormal [123 I]MIBG had higher PDRP z score change per year ($P = 0.027$) and




FIG. 1. Parkinson's disease-related brain pattern (PDRP) z score (baseline to follow-up). (A) Subjects with normal [^{123}I]meta-iodobenzylguanidine scintigraphy ([^{123}I]MIBG) and [^{123}I]N- ω -fluoropropyl-2 β -carbomethoxy-3 β -(4-iodophenyl)nortropane single-photon emission computed tomography ([^{123}I]FP-CIT-SPECT). (B) Subjects with abnormal [^{123}I]MIBG and normal [^{123}I]FP-CIT-SPECT. (C) Subjects with abnormal [^{123}I]MIBG and [^{123}I]FP-CIT-SPECT; bold line marks the phenoconverted subjects (range: -2.0 to 5.0 months after follow-up [^{18}F]fluorodeoxyglucose-positron emission tomography ([^{18}F]FDG-PET)).

higher PDRP z scores at baseline ($P = 0.048$) and follow-up ($P = 0.006$) compared with those with normal [^{123}I]MIBG. PDRP expression in the subjects with abnormal [^{123}I]MIBG was higher at follow-up than at baseline ($P < 0.001$). Only a trend of higher follow-up PDRP z scores was observed in the subjects with normal [^{123}I]MIBG ($P = 0.063$).

[^{123}I]FP-CIT-SPECT

Nine of 12 (75%) subjects with pathological [^{123}I]MIBG had pathological baseline [^{123}I]FP-CIT-SPECTs. All subjects with normal [^{123}I]MIBG had normal baseline [^{123}I]FP-CIT-SPECT. Dopamine transporter (DAT)-binding ratios were lower in subjects with abnormal [^{123}I]MIBG (lowest putaminal value: $P = 0.010$; lowest caudal value: $P = 0.004$).

Olfaction

Subjects with abnormal [^{123}I]MIBG had lower odor identification scores at baseline compared with subjects with normal [^{123}I]MIBG, although this was not statistically significant ($P = 0.053$). The olfactory function in subjects with abnormal [^{123}I]MIBG deteriorated from baseline to follow-up, but this change did not reach statistical significance ($P = 0.063$). At follow-up, subjects with abnormal [^{123}I]MIBG had lower odor identification scores compared with subjects with normal [^{123}I]MIBG ($P = 0.003$). See also Supporting Information Fig. S2. Baseline and follow-up UPDRS-III and MoCA scores did not differ significantly between the two subgroups. At follow-up, two subjects with iRBD fulfilled

the research criteria of probable mild cognitive impairment-Lewy body type.²⁸

PD Phenoconverters

All three subjects who phenoconverted to PD during the study had abnormal [^{123}I]MIBG and [^{123}I]FP-CIT-SPECT, suprathreshold PDRP z scores, and hyposmia at baseline and follow-up (Fig. 1C; Supporting Information Table S1). Their baseline PDRP expressions were among the highest six PDRP z scores. At follow-up, they exhibited the highest PDRP z scores of the iRBD cohort.

For correlation analysis and the individual UPDRS-III scores at baseline and follow-up, see the Supporting Information.

Discussion

This longitudinal pilot study demonstrates that [^{123}I]MIBG, a proxy for cardiac noradrenergic innervation, is associated with the prodromal progression of PDRP expression in iRBD, the latter was recently reported by our group.¹⁸ According to [^{123}I]MIBG results, we identified two subgroups.

In the first, defined by a pathological [^{123}I]MIBG, the majority (75%) had a pathological [^{123}I]FP-CIT-SPECT, 92% presented with suprathreshold follow-up PDRP z scores and 83% had hyposmia. Conversely, the second subgroup with normal [^{123}I]MIBG always had normal [^{123}I]FP-CIT-SPECT, exhibited only mild PDRP z score progression, and mostly had normosmia.

Olfactory function correlated to [^{123}I]MIBG–heart-to-mediastinum ratio values and PDRP z scores at baseline and follow-up. Cognitive and motor scores did not change significantly in either subgroup because of short follow-up time.

Studies of iRBD cohorts showed cardiac noradrenergic denervation in >80% of subjects^{20,22} that has been observed before dopaminergic denervation, in concordance with Braak's PD staging model.^{21,22,29}

Accordingly, we identified three cases with pathological [^{123}I]MIBG but normal [^{123}I]FP-CIT-SPECT. All subjects with reduced DAT binding had pathological [^{123}I]MIBG. As previously published,³⁰ [^{123}I]MIBG and [^{123}I]FP-CIT-SPECT results were found to highly correlate to each other. Patients with iRBD with pathological [^{123}I]MIBG but normal [^{123}I]FP-CIT-SPECT may represent an early stage of prodromal PD in which brainstem structures at the level of the vagal nuclei and/or locus coeruleus have already been affected, but the nigrostriatal pathway is undisturbed or only mildly disturbed. Our findings are in line with the literature^{21,22} and the hypothesis of a “body-first” PD of which iRBD represents a prodromal stage subtype.³¹ Alternatively, some early DLB cases have been known to present with normal striatal DAT binding.^{21,32}

The PDRP is very similar to the [^{18}F]FDG-PET-derived DLB-related pattern (unpublished data).¹⁰ However, it may not detect metabolic changes present in prodromal MSA. Therefore, some subjects with normal [^{123}I]MIBG (and normal [^{123}I]FP-CIT-SPECT) and subthreshold PDRP expression may possibly be in the prenigrostriatal MSA stages. Alternatively, they could represent nonphenoconverters or subjects with slow disease progression. The borderline suprathreshold PDRP expression at follow-up in one of this subgroup may be attributable to advancing age (for details, see Supporting Information).

[^{123}I]MIBG seems to be superior to [^{123}I]FP-CIT-SPECT in identifying subjects with suprathreshold follow-up PDRP z score in an earlier disease stage. This is illustrated by the fact that pathological [^{123}I]MIBG identified more subjects (92%) with suprathreshold follow-up PDRP z score than pathological [^{123}I]FP-CIT-SPECT alone (75%). Because the effectiveness of disease-modifying therapy may be higher in a prodromal “pre-nigral” stage of PD/DLB, [^{123}I]MIBG could function as a state marker to identify subjects with iRBD presenting the prodromal “peripheral” PD/DLB type. Complementarily, the cerebral [^{18}F]FDG-PET is a state marker¹⁰ that may be able to differentiate between parkinsonian disorders¹⁴ and is a prodromal progression marker¹⁸ that is needed to measure the therapy effect. In contrast, [^{123}I]FP-CIT-SPECT is a state^{8,9,33} and a progression marker³⁴ but detects converters later when nigrostriatal degeneration has occurred. Based on the three phenoconverted subjects, pathological

[^{123}I]MIBG, pathological [^{123}I]FP-CIT-SPECT, suprathreshold PDRP z score, and hyposmia together indicate a high risk for phenoconversion to manifest PD.

This study has several limitations: (1) the small sample size, (2) the lack of repeated [^{123}I]MIBGs and [^{123}I]FP-CIT-SPECTs, and (3) the need of a longer follow-up period to clarify the etiology and course of subjects with normal imaging and low PDRP z score. As discussed earlier, those subjects may represent prodromal MSA, slow disease developers, or nonphenoconverters. Finally, this study focuses on a subtype of prodromal α -synucleinopathies, iRBD. Thus, our findings may not be generalizable to other prodromal PD subtypes.

In conclusion, pathological [^{123}I]MIBG appears to indicate prodromal progression of PDRP expression earlier than [^{123}I]FP-CIT-SPECT and is associated with hyposmia in iRBD. Therefore, we propose cardiac [^{123}I]MIBG as an early stratifying variable in iRBD research, provided that our results are confirmed by a larger, prospective, multicenter study. ■

Acknowledgments: This study was supported by Dutch “Stichting ParkinsonFonds” and the German “ParkinsonFonds Deutschland,” and we thank them for their support. The funders of this study did not have any role in designing the study; collecting, analyzing, or interpreting the data; or writing the article. The corresponding author had access to and accepted responsibility for all the relevant data that were submitted for publication. We thank Laura K. Teune, Fransje E. Reesink, and Jelmer G. Kok for recruiting healthy control subjects in the FDG-PET part of this study. We are grateful to David Vázquez García and Débora E. Peretti for participating in writing the in-house code used in the FDG-PET analysis. Open access funding enabled and organized by Projekt DEAL.

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

References

1. Schenck CH, Boeve BF, Mahowald MW. Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series. *Sleep Med* 2013;14(8):744–748.
2. Iranzo A, Fernández-Arcos A, Tolosa E, et al. Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: study in 174 patients. *PLoS One* 2014;9(2):e89741
3. Postuma RB, Iranzo A, Hu M, et al. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. *Brain* 2019;142(3):744–759.
4. Miyamoto T, Miyamoto M, Iwanami M, et al. Olfactory dysfunction in idiopathic REM sleep behavior disorder. *Sleep Med* 2010;11(5):458–461.
5. Stiasny-Kolster K, Doerr Y, Möller JC, et al. Combination of ‘idiopathic’ REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. *Brain* 2005;128(Pt 1):126–137.
6. Kashihara K, Imamura T, Shinya T. Cardiac 123I-MIBG uptake is reduced more markedly in patients with REM sleep behavior disorder than in those with early stage Parkinson's disease. *Parkinsonism Relat Disord* 2010;16(4):252–255.

7. Miyamoto T, Miyamoto M, Iwanami M, Hirata K. Follow-up study of cardiac ^{123}I -MIBG scintigraphy in idiopathic REM sleep behavior disorder. *Eur J Neurol* 2011;18(10):1275–1278.
8. Iranzo A, Santamaría J, Valldeoriola F, et al. Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder. *Ann Neurol* 2017;82(3):419–428.
9. Arnaldi D, Chincarini A, Hu MT, et al. Dopaminergic imaging and clinical predictors for phenocopy of REM sleep behaviour disorder. *Brain* 2021;144(1):278–287.
10. Meles SK, Vadasz D, Renken RJ, et al. FDG PET, dopamine transporter SPECT, and olfaction: combining biomarkers in REM sleep behavior disorder. *Mov Disord* 2017;32(10):1482–1486.
11. Meles SK, Renken RJ, Janzen A, et al. The metabolic pattern of idiopathic REM sleep behavior disorder reflects early-stage Parkinson disease. *J Nucl Med* 2018;59(9):1437–1444.
12. Spetsieris P, Ma Y, Peng S, et al. Identification of disease-related spatial covariance patterns using neuroimaging data. *J Vis Exp* 2013; 76:50319. <https://doi.org/10.3791/50319>
13. Eidelberg D. Metabolic brain networks in neurodegenerative disorders: a functional imaging approach. *Trends Neurosci* 2009;32(10): 548–557.
14. Teune LK, Renken RJ, Mudali D, et al. Validation of parkinsonian disease-related metabolic brain patterns. *Mov Disord* 2013;28(4): 547–551.
15. Meles SK, Renken RJ, Pagani M, et al. Abnormal pattern of brain glucose metabolism in Parkinson's disease: replication in three European cohorts. *Eur J Nucl Med Mol Imaging* 2020;47(2):437–450.
16. Holtbernd F, Gagnon JF, Postuma RB, et al. Abnormal metabolic network activity in REM sleep behavior disorder. *Neurology* 2014; 82(7):620–627.
17. Schindlbeck KA, Eidelberg D. Network imaging biomarkers: insights and clinical applications in Parkinson's disease. *Lancet Neurol* 2018;17(7):629–640.
18. Kogan RV, Janzen A, Meles SK, et al. Four-year follow-up of [^{18}F] Fluorodeoxyglucose positron emission tomography-based Parkinson's disease-related pattern expression in 20 patients with isolated rapid eye movement sleep behavior disorder shows prodromal progression. *Mov Disord* 2021;36(1):230–235.
19. Orimo S, Suzuki M, Inaba A, Mizusawa H. ^{123}I -MIBG myocardial scintigraphy for differentiating Parkinson's disease from other neurodegenerative parkinsonism: a systematic review and meta-analysis. *Parkinsonism Relat Disord* 2012;18(5):494–500.
20. Miyamoto T, Miyamoto M, Suzuki K, Nishibayashi M, Iwanami M, Hirata K. ^{123}I -MIBG cardiac scintigraphy provides clues to the underlying neurodegenerative disorder in idiopathic REM sleep behavior disorder. *Sleep* 2008;31(5):717–723.
21. Sakakibara R, Tateno F, Aiba Y, et al. MIBG myocardial Scintigraphy identifies premotor PD/DLB during a negative DAT scan period: second report. *Mov Disord Clin Pract* 2019;6(1):46–50.
22. Knudsen K, Fedorova TD, Hansen AK, et al. In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study. *Lancet Neurol* 2018;17(7):618–628.
23. Iijima M, Osawa M, Momose M, et al. Cardiac sympathetic degeneration correlates with olfactory function in Parkinson's disease. *Mov Disord* 2010;25(9):1143–1149.
24. Mizutani Y, Nakamura T, Okada A, et al. Hyposmia and cardiovascular dysautonomia correlatively appear in early-stage Parkinson's disease. *Parkinsonism Relat Disord* 2014;20(5):520–524.
25. Mahlknecht P, Pechlaner R, Boesveldt S, et al. Optimizing odor identification testing as quick and accurate diagnostic tool for Parkinson's disease. *Mov Disord* 2016;31(9):1408–1413.
26. Gagnon JF, Postuma RB, Joncas S, Desjardins C, Latreille V. The Montreal cognitive assessment: a screening tool for mild cognitive impairment in REM sleep behavior disorder. *Mov Disord* 2010; 25(7):936–940.
27. Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease. The unified Parkinson's disease rating scale (UPDRS): status and recommendations. *Mov Disord* 2003;18(7):738–750.
28. McKeith IG, Ferman TJ, Thomas AJ, et al. Research criteria for the diagnosis of prodromal dementia with Lewy bodies. *Neurology* 2020;94(17):743–755.
29. Braak H, del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. *Neurobiol Aging* 2003;24(2):197–211.
30. Nihashi T, Ito K, Terasawa T. Diagnostic accuracy of DAT-SPECT and MIBG scintigraphy for dementia with Lewy bodies: an updated systematic review and Bayesian latent class model meta-analysis. *Eur J Nucl Med Mol Imaging* 2020;47(8):1984–1997.
31. Horsager J, Andersen KB, Knudsen K, et al. Brain-first versus body-first Parkinson's disease: a multimodal imaging case-control study. *Brain* 2020;143(10):3077–3088.
32. van der Zande JJ, Booij J, Scheltens P, Raijmakers PG, Lemstra AW. [(123)I]FP-CIT SPECT scans initially rated as normal became abnormal over time in patients with probable dementia with Lewy bodies. *Eur J Nucl Med Mol Imaging* 2016;43(6):1060–1066.
33. Chahine LM, Brumm MC, Caspell-Garcia C, et al. Dopamine transporter imaging predicts clinically-defined α -synucleinopathy in REM sleep behavior disorder. *Ann Clin Transl Neurol* 2021;8(1):201–212.
34. Iranzo A, Valldeoriola F, Lomeña F, et al. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. *Lancet Neurol* 2011;10(9):797–805.

Supporting Data

Additional Supporting Information may be found in the online version of this article at the publisher's web-site.

SGML and CITI Use Only DO NOT PRINT

Author Roles

K.L.L., W.H.O., G.M., F.F.G., M.L., J.B., S.K.M., and R.V.K. assisted in the study protocol and design. K.L.L. and W.H.O. secured the funding for this project. A.J. and E.S. recruited patients. E.S. organized and accompanied German patients on visits to Groningen for [^{18}F]FDG-PET imaging. R.V.K. organized all logistics and imaging appointments for patients in Groningen. A.J., F.F.G. and G.M. recruited patients with iRBD and performed the analysis of the polysomnography. A.J. performed all neuroclinical assessments with German patients in Marburg. J.B. interpreted all [^{123}I]FP-CIT-SPECT data, while M.L. and G.S. interpreted all [^{123}I]MIBG scintigraphy data. A.J. and R.V.K. performed the statistical analyses with help from R.J.R. and F.F.G. and put together all figures and tables; Fig. 1 was also made with input from S.K.M. R.J.R. wrote the in-house code used. A.J. and R.V.K. drafted the manuscript. All authors contributed commentary for revising the manuscript.

Financial Disclosures of All Authors (for the Preceding 12 Months)

Annette Janzen, MD, reports grants from ParkinsonFonds Deutschland outside the submitted work. Rosalie V. Kogan, MD, reports grants from Stichting ParkinsonFonds during conduct of the study. Sanne K. Meles, MD, reports grants from Stichting ParkinsonFonds during conduct of the study and outside the submitted work. Elisabeth Sittig reports no competing interests. Remco J. Renken, PhD, reports no competing interests. Fanni F. Geibl, MD, PhD, reports no competing interests. Jan Booij, MD, PhD, reports that he is a consultant for GE Healthcare (all payments to his institution). Gilles Stormezand, MD, reports no competing interests. Markus Luster, MD, reports no competing interests. Geert Mayer, MD, reports no competing interests. Klaus L. Leenders, MD, PhD, reports grants from Stichting ParkinsonFonds, the Netherlands and The Michael J. Fox Foundation, USA. Wolfgang H. Oertel, MD, PhD, reports grants from ParkinsonFonds Deutschland, The Michael J. Fox Foundation, and Deutsche Forschungsgemeinschaft (DFG) during the conduct of the study; personal fees from Adamas, MODAG, Roche, and UCB outside the submitted work; and is a Hertie-Senior-Research Professor supported by the Charitable Hertie-Foundation, Frankfurt/Main, Germany.